Evidence map›Paper›PMID 35891518›Full record

ArticleViruses2022

Galectin-9 and Interferon-Gamma Are Released by Natural Killer Cells upon Activation with Interferon-Alpha and Orchestrate the Suppression of Hepatitis C Virus Infection.

Anna Paola Carreca, Massimiliano Gaetani, Rosalia Busà, Maria Giovanna Francipane, Maria Rita Gulotta, Ugo Perricone, Gioacchin Iannolo, Giovanna Russelli, Claudia Carcione, Pier Giulio Conaldi and 1 more

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Galectins and Liver Diseases.International journal of molecular sciences · 2025
    Review
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Anna Paola CarrecaFondazione Ri.MED, 90133 Palermo, Italy.ORCID 0000-0002-7389-7555
Massimiliano GaetaniFondazione Ri.MED, 90133 Palermo, Italy.
Rosalia BusàDepartment of Research, IRCCS-ISMETT, Istituto Mediterraneo per i Trapianti e Terapie Ad Alta Specializzazione, 90127 Palermo, Italy.ORCID 0000-0002-7546-7209
Maria Giovanna FrancipaneFondazione Ri.MED, 90133 Palermo, Italy.ORCID 0000-0002-7194-7918
Maria Rita GulottaFondazione Ri.MED, 90133 Palermo, Italy.ORCID 0000-0001-5032-4888
Ugo PerriconeFondazione Ri.MED, 90133 Palermo, Italy.
Gioacchin IannoloDepartment of Research, IRCCS-ISMETT, Istituto Mediterraneo per i Trapianti e Terapie Ad Alta Specializzazione, 90127 Palermo, Italy.ORCID 0000-0002-7710-4735
Giovanna RusselliDepartment of Research, IRCCS-ISMETT, Istituto Mediterraneo per i Trapianti e Terapie Ad Alta Specializzazione, 90127 Palermo, Italy.ORCID 0000-0002-1920-0892
Claudia CarcioneFondazione Ri.MED, 90133 Palermo, Italy.
Pier Giulio ConaldiDepartment of Research, IRCCS-ISMETT, Istituto Mediterraneo per i Trapianti e Terapie Ad Alta Specializzazione, 90127 Palermo, Italy.ORCID 0000-0003-1994-8005
Ester BadamiFondazione Ri.MED, 90133 Palermo, Italy.ORCID 0000-0002-0154-6270
Ri.MED · ITIstituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione · ITScience for Life Laboratory · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural killer (NK) cells mount an immune response against hepatitis C virus (HCV) infection and can be activated by several cytokines, including interleukin-2 (IL-2), IL-15, and interferon-alpha (IFN-α). By exploiting the Huh7.5 hepatoma cell line infected with the HCV JFH1 genome, we provide novel insights into the antiviral effector functions of human primary NK cells after cytokine stimulation. NK cells activated with IFN-α (IFNα-NKs) had enhanced contact-dependent and -independent responses as compared with NK cells activated with IL-2/IL-15 (IL2/IL15-NKs) and could inhibit HCV replication both in vitro and in vivo. Importantly, IFN-α, but not IL-2/IL-15, protected NK cells from the functional inhibition exerted by HCV. By performing flow cytometry, multiplex cytokine profiling, and mass-spectrometry-based proteomics, we discovered that IFNα-NKs secreted high levels of galectin-9 and interferon-gamma (IFN-γ), and by conducting neutralization assays, we confirmed the major role of these molecules in HCV suppression. We speculated that galectin-9 might act extracellularly to inhibit HCV binding to host cells and downstream infection. In silico approaches predicted the binding of HCV envelope protein E2 to galectin-9 carbohydrate-recognition domains, and co-immunoprecipitation assays confirmed physical interaction. IFN-γ, on the other hand, triggered the intracellular expressions of two antiviral gate-keepers in target cells, namely, myxovirus-1 (MX1) and interferon-induced protein with tetratricopeptide repeats 1 (IFIT1). Collectively, our data add more complexity to the antiviral innate response mediated by NK cells and highlight galectin-9 as a key molecule that might be exploited to neutralize productive viral infection.

Indexed as

HepacivirusHepatitis CAntiviral AgentsCytokinesGalectinsHumansInterferon-alphaInterferon-gammaInterleukin-15Killer Cells, NaturalAntiviral AgentsCytokinesGalectinsInterferon-alphaInterferon-gammaInterleukin-15galectin-9HCVIFN-αIFN-γNK cells

Identifiers

PMID35891518
PMCPMC9317111
OpenAlexW4285595592

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.